The DOI matches its Crossref record; 332 of the 332 references it cites were found in a registry or an index.
A Modern Approach to Dyslipidemia
Open accessAbstract
Lipid disorders involving derangements in serum cholesterol, triglycerides, or both are commonly encountered in clinical practice and often have implications for cardiovascular risk and overall health. Recent advances in knowledge, recommendations, and treatment options have necessitated an updated approach to these disorders. Older classification schemes have outlived their usefulness, yielding to an approach based on the primary lipid disturbance identified on a routine lipid panel as a practical starting point. Although monogenic dyslipidemias exist and are important to identify, most individuals with lipid disorders have polygenic predisposition, often in the context of secondary factors such as obesity and type 2 diabetes. With regard to cardiovascular disease, elevated low-density lipoprotein cholesterol is essentially causal, and clinical practice guidelines worldwide have recommended treatment thresholds and targets for this variable. Furthermore, recent studies have established elevated triglycerides as a cardiovascular risk factor, whereas depressed high-density lipoprotein cholesterol now appears less contributory than was previously believed. An updated approach to diagnosis and risk assessment may include measurement of secondary lipid variables such as apolipoprotein B and lipoprotein(a), together with selective use of genetic testing to diagnose rare monogenic dyslipidemias such as familial hypercholesterolemia or familial chylomicronemia syndrome. The ongoing development of new agents—especially antisense RNA and monoclonal antibodies—targeting dyslipidemias will provide additional management options, which in turn motivates discussion on how best to incorporate them into current treatment algorithms.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Items 201–332 of 332
Johansen, C. T., Wang, J., Lanktree, M. B., McIntyre, A. D., Ban, M. R., Martins, R. A., Kennedy, B. A., Hassell, R. G., Visser, M. E., Schwartz, S. M., et al. (2011) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.111.226365 · Cited by 97
Self-citationSteyrer, E., Durovic, S., Frank, S., Giessauf, W., Burger, A., Dieplinger, H., Zechner, R., & Kostner, G. M. (1994) · Journal of Clinical Investigation · doi:10.1172/jci117598 · Cited by 97
Lipoprotein disorders and cardiovascular risk
Genest, J. J. (2003) · Journal of Inherited Metabolic Disease · doi:10.1023/a:1024449603891 · Cited by 94
Yang, F., Wang, Y., Sternfeld, L., Rodriguez, J. A., Ross, C., Hayden, M. R., Carriere, F., Liu, G., & Schulz, I. (2009) · Acta Physiologica · doi:10.1111/j.1748-1716.2008.01933.x · Cited by 93 · cited 1×
“Although the underlying pathophysiology is not understood, it could be related to abnormal lipolysis by mislocalized exocrine pancreatic lipase, leading to pancreatic autodigestion and inflammation (80).”
BackgroundFamilial lipoprotein lipase deficiency in infancy: Clinical, biochemical, and molecular study
Feoli‐Fonseca, J. C., Levy, E. H., Godard, M., & Lambert, M. A. (1998) · The Journal of Pediatrics · doi:10.1016/s0022-3476(98)70280-x · Cited by 93
Garuti, R., Jones, C., Li, W.-P., Michaely, P., Herz, J., Gerard, R. D., Cohen, J. C., & Hobbs, H. H. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509394200 · Cited by 91
Cholesterol and hepatic lipoprotein assembly and secretion
Kang, S. (2000) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/s1388-1981(00)00151-7 · Cited by 90
Insulin Therapy for a Non-Diabetic Patient with Severe Hypertriglyceridemia
Jabbar, M. A., Zuhri-Yafi, M. I., & Larrea, J. (1998) · Journal of the American College of Nutrition · doi:10.1080/07315724.1998.10718794 · Cited by 90
Iuliano, L., Mauriello, A., Sbarigia, E., Spagnoli, L. G., & Violi, F. (2000) · Circulation · doi:10.1161/01.cir.101.11.1249 · Cited by 89
Monogenic pediatric dyslipidemias: Classification, genetics and clinical spectrum
Rahalkar, A. R., & Hegele, R. A. (2007) · Molecular Genetics and Metabolism · doi:10.1016/j.ymgme.2007.10.007 · Cited by 88
Self-citationKent, S. T., Rosenson, R. S., Avery, C. L., Chen, Y.-D. I., Correa, A., Cummings, S. R., Cupples, L. A., Cushman, M., Evans, D. S., Gudnason, V., et al. (2017) · Circulation: Cardiovascular Genetics · doi:10.1161/circgenetics.116.001632 · Cited by 86
TREATMENT OF SEVERE DIABETIC HYPERTRIGLYCERIDÆMIA BY PLASMA EXCHANGE
Betteridge, D. J., Bakowski, M. T., Taylor, K. G., Reckless, J. P. D., Silva, S. R. D., & Galton, D. J. (1978) · The Lancet · doi:10.1016/s0140-6736(78)92450-9 · Cited by 85
Tyroler, H. A., Glueck, C. J., Christensen, B., & Kwiterovich, P. O. (1980) · PubMed · Cited by 84
Wan, J., He, W., Zhu, Y., Zhu, Y., Zeng, H., Liu, P., Xia, L., & Lü, N. (2017) · Lipids in Health and Disease · doi:10.1186/s12944-017-0517-3 · Cited by 82
Esan, O., & Wierzbicki, A. S. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s224771 · Cited by 82
Albers, J. J., Kennedy, H., & Marcovina, S. M. (1996) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)37647-1 · Cited by 80
Lomitapide for the treatment of hypercholesterolemia
Berberich, A. J., & Hegele, R. A. (2017) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2017.1340941 · Cited by 79
Self-citationMazidi, M., Rezaie, P., Karimi, E., & Kengne, A. P. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.10.011 · Cited by 77
Stahel, P., Xiao, C., Hegele, R. A., & Lewis, G. F. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2017.12.007 · Cited by 75
Self-citationCharles, E. C., Olson, K. L., Sandhoff, B. G., McClure, D. L., & Merenich, J. A. (2005) · The American Journal of Medicine · doi:10.1016/j.amjmed.2005.02.008 · Cited by 74
Hypertriglyceridemia: phenomics and genomics
Hegele, R. A., & Pollex, R. L. (2009) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-008-0005-1 · Cited by 72
Self-citationCombined hyperlipidemia: familial but not (usually) monogenic
Brahm, A. J., & Hegele, R. A. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000270 · Cited by 71
Self-citationApolipoprotein C-III: Going Back to the Future for a Lipid Drug Target
Huff, M. W., & Hegele, R. A. (2013) · Circulation Research · doi:10.1161/circresaha.113.301464 · Cited by 70
Self-citationMancini, G. B. J., Hegele, R. A., & Leiter, L. A. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.019 · Cited by 70
Self-citationThe role of genetic testing in dyslipidaemia
Berberich, A. J., & Hegele, R. A. (2018) · Pathology · doi:10.1016/j.pathol.2018.10.014 · Cited by 69
Self-citationMechanism of action of anti-hypercholesterolemia drugs and their resistance
Tiwari, V., & Khokhar, M. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.07.048 · Cited by 68
Bempedoic acid: effects on lipoprotein metabolism and atherosclerosis
Burke, A. C., Telford, D. E., & Huff, M. W. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000565 · Cited by 68
ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets
Akoumianakis, I., Zvintzou, E., Kypreos, K. E., & Filippatos, T. D. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00914-7 · Cited by 68
Conservative management in hypertriglyceridemia-associated pancreatitis
Berberich, A. J., Ziada, A., Zou, G. Y., & Hegele, R. A. (2019) · Journal of Internal Medicine · doi:10.1111/joim.12925 · Cited by 67
Self-citationLiu, Q. K. (2021) · Journal of clinical lipidology · doi:10.1016/j.jacl.2021.05.007 · Cited by 66
Polygenic determinants in extremes of high-density lipoprotein cholesterol
Dron, J. S., Wang, J., Low‐Kam, C., Khetarpal, S. A., Robinson, J. F., McIntyre, A. D., Ban, M. R., Cao, H., Rhainds, D., Dubé, M., et al. (2017) · Journal of Lipid Research · doi:10.1194/jlr.m079822 · Cited by 65
Self-citationWang, J., Ban, M. R., Kennedy, B. A., Anand, S. S., Yusuf, S., Huff, M. W., Pollex, R. L., & Hegele, R. A. (2008) · Nature Clinical Practice Cardiovascular Medicine · doi:10.1038/ncpcardio1326 · Cited by 63
Self-citationMicrosomal transfer protein inhibition in humans
Cuchel, M., & Rader, D. J. (2013) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e32836139df · Cited by 62
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61 · cited 1×
“For the majority of patients screened without HTG, a nonfasting profile provides an accurate estimate—to within <5% error— of LDL-C (111).”
BackgroundGenetic, biochemical, and clinical features of LCAT deficiency: update for 2020
Pavanello, C., & Calabresi, L. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000697 · Cited by 59
Ahmad, Z., Pordy, R. C., Rader, D. J., Gaudet, D., Ali, S., Gonzaga-Jauregui, C. G., Ponda, M. P., Shumel, B. S., Banerjee, P., & Dunbar, R. L. (2021) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.04.091 · Cited by 59
Chylomicron retention disease: genetics, biochemistry, and clinical spectrum
Levy, E. H., Poinsot, P., & Spahis, S. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000578 · Cited by 58
Apolipoprotein C-II: the re-emergence of a forgotten factor
Wolska, A. T., Reimund, M., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000680 · Cited by 58
The polygenic nature of mild-to-moderate hypertriglyceridemia
Dron, J. S., Wang, J., McIntyre, A. D., Cao, H., & Hegele, R. A. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.01.003 · Cited by 57
Self-citationNiacin: another look at an underutilized lipid-lowering medication
Creider, J. C., Hegele, R. A., & JOY, T. R. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.22 · Cited by 55
Self-citationHypertriglyceridemia: new approaches in management and treatment
Wolska, A. T., Yang, Z., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000710 · Cited by 54
Zhao, B., Song, J., & Ghosh, S. (2008) · Journal of Lipid Research · doi:10.1194/jlr.m800277-jlr200 · Cited by 53
Proprotein convertase subtilisin/kexin type 9 and lipid metabolism
Spolitu, S., Dai, W., Zadroga, J. A., & Özcan, L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000601 · Cited by 53
LDL Apheresis and Lp (a) Apheresis: A Clinician’s Perspective
Kayıkçıoğlu, M. (2021) · Current Atherosclerosis Reports · doi:10.1007/s11883-021-00911-w · Cited by 53
Regulation of Intracellular Cholesterol Metabolism.
Sato, R., & Takano, T. (1995) · Cell Structure and Function · doi:10.1247/csf.20.421 · Cited by 52
Au, D. T., Strickland, D. K., & Muratoglu, S. C. (2017) · Journal of Diabetes Research · doi:10.1155/2017/8356537 · Cited by 51
More accurate LDL-C calculation: Externally validated, guideline endorsed
Brownstein, A. J., & Martin, S. S. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.030 · Cited by 51
Oh, I., Hur, J. K., Ryoo, J., Jung, J. Y., Park, S. K., Yang, H. J., Choi, J., Jung, K., Won, Y., & Oh, C. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.01.035 · Cited by 50
Sniderman, A. D., Langlois, M., & Cobbaert, C. M. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000754 · Cited by 50
Incidence of cardiovascular disease in familial combined hyperlipidemia: A 15-year follow-up study
Luijten, J., van Greevenbroek, M. M. J., Schaper, N. C., Meex, S. J. R., van der Steen, C., Meijer, L. J., de Boer, D., Graaf, J. D., Stehouwer, C. D. A., & Brouwers, M. C. G. J. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.013 · Cited by 48
From HDL-cholesterol to HDL-function: cholesterol efflux capacity determinants
Rhainds, D., & Tardif, J. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000589 · Cited by 46
Combined hyperlipidemia is genetically similar to isolated hypertriglyceridemia
Gill, P. K., Dron, J. S., Berberich, A. J., Wang, J., McIntyre, A. D., Cao, H., & Hegele, R. A. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.11.006 · Cited by 45
Self-citationExtreme hypertriglyceridemia: genetic diversity, pancreatitis, pregnancy, and prevalence
Chyzhyk, V., Kozmic, S., Brown, A. S., Hudgins, L. C., Starc, T. J., Davila, A. D., Blevins, T. C., Diffenderfer, M. R., He, L., Geller, A. S., et al. (2019) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2018.09.007 · Cited by 44
Self-citationBempedoic acid for the treatment of dyslipidemia
Marrs, J. C., & Anderson, S. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-6-5 · Cited by 44
ApoB in clinical care: Pro and Con
Sniderman, A. D., & Robinson, J. G. (2018) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2018.11.001 · Cited by 43
Tangier disease: update for 2020
Hooper, A. J., Hegele, R. A., & Burnett, J. R. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000669 · Cited by 43
Self-citationFamilial combined hypolipidemia: angiopoietin-like protein-3 deficiency
Arca, M., D’Erasmo, L., & Minicocci, I. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000668 · Cited by 43
Extreme hypertriglyceridemia managed with insulin
Thuzar, M., Shenoy, V. V., Malabu, U. H., Schrale, R. G., & Sangla, K. S. (2014) · Journal of clinical lipidology · doi:10.1016/j.jacl.2014.09.004 · Cited by 42
Genetics of hypertriglyceridemia and atherosclerosis
Gill, P. K., Dron, J. S., & Hegele, R. A. (2021) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000839 · Cited by 41
Self-citationKawashiri, M., Higashikata, T., Mizuno, M., Takata, M., Katsuda, S., Miwa, K., Nozue, T., Nohara, A., Inazu, A., Kobayashi, J., et al. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-1098 · Cited by 40
Reeskamp, L. F., Tromp, T. R., & Stroes, E. S. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000679 · Cited by 40
The biochemical and genetic diagnosis of lipid disorders
Schaefer, E. J., Geller, A. S., & Endress, G. A. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000590 · Cited by 39
Evidence for improved survival with treatment of homozygous familial hypercholesterolemia
Bélanger, A. M., Akioyamen, L. E., Alothman, L., & Genest, J. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000686 · Cited by 38
Advances in familial hypercholesterolaemia in children
Reijman, M. D., Kusters, D. M., & Wiegman, A. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00095-x · Cited by 38
Remnant lipoproteins and atherosclerotic cardiovascular disease
Tada, H., Nohara, A., Inazu, A., Mabuchi, H., & Kawashiri, M.-A. (2019) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.12.014 · Cited by 37
Hypertriglyceridemia: Risks and perspectives
Gotto, A. M. (1992) · The American Journal of Cardiology · doi:10.1016/0002-9149(92)91086-j · Cited by 37
The Pathophysiology of Pancreatitis
Khokhar, A. S., & Seidner, D. L. (2004) · Nutrition in Clinical Practice · doi:10.1177/011542650401900105 · Cited by 35
Langsted, A., & Nordestgaard, B. G. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000681 · Cited by 34
Zheng, K. H., Kaiser, Y., van Olden, C. C., Santos, R. D., Dasseux, J., Genest, J. J., Gaudet, D., Westerink, J., Keyserling, C., Verberne, H. J., et al. (2020) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2020.08.004 · Cited by 34
Self-citationVolanesorsen, Familial Chylomicronemia Syndrome, and Thrombocytopenia
Khetarpal, S. A., Wang, M., & Khera, A. V. (2019) · New England Journal of Medicine · doi:10.1056/nejmc1912350 · Cited by 33
Characterization of a novel mutation causing hepatic lipase deficiency among French Canadians
Ruel, I. L., Couture, P., Gagné, C., Deshaies, Y., Simard, J., Hegele, R. A., & Lamarche, B. (2003) · Journal of Lipid Research · doi:10.1194/jlr.m200479-jlr200 · Cited by 32
Self-citationLomitapide for the treatment of hypertriglyceridemia
Berberich, A. J., & Hegele, R. A. (2016) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2016.1254187 · Cited by 31
Self-citationGarg, A., Garg, V., Hegele, R. A., & Lewis, G. F. (2019) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(19)30156-1 · Cited by 31
Self-citationYamashita, S., & Matsuzawa, Y. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000332 · Cited by 30
Tardif, J., Dubé, M., Pfeffer, M. A., Waters, D. D., Köenig, W., Maggioni, A. P., McMurray, J. J. V., Mooser, V., White, H. D., Heinonen, T. M., et al. (2020) · American Heart Journal · doi:10.1016/j.ahj.2020.01.007 · Cited by 30
Genest, J. J., Corbett, H. M., McNamara, J. R., Schaefer, M. M., Salem, D. N., & Schaefer, E. J. (1988) · The American Journal of Cardiology · doi:10.1016/0002-9149(88)90114-2 · Cited by 29
What Is the Role of Advanced Lipoprotein Analysis in Practice?
Robinson, J. G. (2012) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.04.067 · Cited by 29
Inhibition of angiopoietin-like 3 for the management of severe hypercholesterolemia
Mohamed, F., Botha, T. C., & Raal, F. J. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000755 · Cited by 29
The value of genetic testing: beyond clinical utility
Lerner, B., Marshall, N. J., Oishi, S., Lanto, A. B., Lee, M. W., Hamilton, A. B., Yano, E. M., & Scheuner, M. T. (2016) · Genetics in Medicine · doi:10.1038/gim.2016.186 · Cited by 28
Lipid Levels in the Post-Acute Coronary Syndrome Setting
Miller, M. J. (2008) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.12.039 · Cited by 27
Pedersen, S. B., Varbo, A., Langsted, A., & Nordestgaard, B. G. (2017) · Journal of Internal Medicine · doi:10.1111/joim.12713 · Cited by 26
Wierzbicki, A. S. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch44 · Cited by 26
Inborn errors of apolipoprotein A-I metabolism: implications for disease, research and development
Zanoni, P., & von Eckardstein, A. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000667 · Cited by 26
Xanthomas: a marker for hyperlipidemias.
Lugo‐Somolinos, A., & Sánchez, J. E. (2004) · PubMed · Cited by 25
HDL modification: recent developments and their relevance to atherosclerotic cardiovascular disease
Wilkins, J. T., & Seckler, H. S. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000571 · Cited by 25
Usefulness of Gemcabene in Homozygous Familial Hypercholesterolemia (from COBALT-1)
Gaudet, D., Durst, R. Y., Lepor, N. E., Bakker-Arkema, R. G., Bisgaier, C. L., Masson, L., Golden, L., Kastelein, J. J. P., Hegele, R. A., & Stein, E. A. (2019) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2019.09.010 · Cited by 25
Self-citationD’Erasmo, L., Gallo, A., Costanzo, A. D., Bruckert, É., & Arca, M. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1787380 · Cited by 25
Novel lecithin:cholesterol acyltransferase-based therapeutic approaches
Freeman, L. A., Karathanasis, S. K., & Remaley, A. T. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000673 · Cited by 24
Cholesterol Absorption and Metabolism
Howles, P. N. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3661-8_11 · Cited by 23
Hegele, R. A., & Dron, J. S. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.313065 · Cited by 22
Self-citationVolanesorsen for treatment of patients with familial chylomicronemia syndrome
Warden, B. A., & Duell, P. B. (2018) · Drugs of today · doi:10.1358/dot.2018.54.12.2899384 · Cited by 20
Update on low-density lipoprotein cholesterol quantification
Chung, S. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000611 · Cited by 20
Low LDL cholesterol—Friend or foe?
Hartz, J. C., Hegele, R. A., & Wilson, D. P. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.006 · Cited by 19
Self-citationMaximizing the benefits of cholesterol-lowering drugs
Feingold, K. R. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000631 · Cited by 19
A Comparative Study of the Therapeutic Effect of Probucol and Pravastatin on Xanthelasma
FUJITA, M., & Shirai, K. (1996) · The Journal of Dermatology · doi:10.1111/j.1346-8138.1996.tb02661.x · Cited by 18
Testing pitfalls and summary of guidance in lipid management
Smellie, W. S. A. (2006) · BMJ · doi:10.1136/bmj.333.7558.83 · Cited by 17
Hyperlipidemia and cardiovascular disease: new insights on lipoprotein(a)
Burkhardt, R. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000594 · Cited by 17
SPPARM alpha: the Lazarus effect
Fruchart, J., & Santos, R. D. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000640 · Cited by 17
Mendelian randomisation, triglycerides, and CHD
Paré, G., & Anand, S. S. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60659-9 · Cited by 16
Meshkini, M., Alaei-Shahmiri, F., Mamotte, C. D. S., & Earnest, J. (2016) · Journal of Immigrant and Minority Health · doi:10.1007/s10903-015-0320-z · Cited by 16
High-density lipoprotein: our elusive friend
Asztalos, B. F., Niisuke, K., & Horvath, K. V. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000612 · Cited by 16
Lipid management beyond the guidelines
Robinson, J. G. (2019) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2019.10.004 · Cited by 16
Is hypertriglyceridemia atherogenic?
Huet, F., Roubille, C., & Roubille, F. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000622 · Cited by 15
Brandts, J., & Ray, K. K. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000691 · Cited by 15
Proprotein convertase subtilisin/kexin type 9 inhibition as the next statin?
Rakipovski, G., Hovingh, G. K., & Nyberg, M. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000718 · Cited by 15
Beeber, L. S. (2002) · AJN American Journal of Nursing · doi:10.1097/00000446-200211000-00033 · Cited by 14
Holewijn, S., Sniderman, A. D., den Heijer, M., Swinkels, D. W., Stalenhoef, A. F. H., & Graaf, J. D. (2010) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2010.02426.x · Cited by 13
Inheritance of high and low HDL: mechanisms and management
Sourlas, A., & Kosmas, C. E. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000610 · Cited by 13
Combination Lipid-Lowering Therapies for the Prevention of Recurrent Cardiovascular Events
Lee, S., & Cannon, C. P. (2018) · Current Cardiology Reports · doi:10.1007/s11886-018-0997-4 · Cited by 12
Boffa, M. B., & Koschinsky, M. L. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000641 · Cited by 12
Ganda, O. P. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000694 · Cited by 12
Human variant of scavenger receptor BI (R174C) exhibits impaired cholesterol transport functions
May, S. C., Dron, J. S., Hegele, R. A., & Sahoo, D. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100045 · Cited by 12
Self-citationNicholls, S. J., & Bubb, K. J. (2021) · Current Cardiology Reports · doi:10.1007/s11886-021-01528-w · Cited by 12
Acquired low cholesterol: diagnosis and relevance to safety of low LDL therapeutic targets
Soran, H., Ho, J. H., & Durrington, P. N. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000526 · Cited by 11
Soran, H., Ho, J. H., Adam, S., & Durrington, P. N. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000614 · Cited by 11
What have we learnt from the clinical outcomes trials with the cetrapibs?
Doggrell, S. A. (2018) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000518 · Cited by 9
Severe Combined Dyslipidemia With a Complex Genetic Basis
Le, R. T., Abbas, M., McIntyre, A. D., & Hegele, R. A. (2019) · Journal of Investigative Medicine High Impact Case Reports · doi:10.1177/2324709619877050 · Cited by 9
Self-citationNicholls, S. J., & Nelson, A. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000712 · Cited by 8
Apolipoprotein genetic variants and hereditary amyloidosis
Jeraj, N., Hegele, R. A., & Berberich, A. J. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000736 · Cited by 8
Self-citationEditorial: Discussing polygenic risk with lipid clinic patients
Dron, J. S., & Hegele, R. A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000768 · Cited by 8
Self-citationCritical appraisal of revised cholesterol guidelines for the very high-risk patient
Rosenson, R. S., & Lloyd‐Jones, D. M. (2005) · Expert Review of Cardiovascular Therapy · doi:10.1586/14779072.1.3.173 · Cited by 7
Strategies to alter the trajectory of atherosclerotic cardiovascular disease
Packard, C. J. (2019) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000643 · Cited by 7
Byrne, P., Cullinan, J., Mintzes, B. J., & Smith, S. M. (2020) · BMJ · doi:10.1136/bmj.m579 · Cited by 6
Soran, H., Cooper, J. A., Durrington, P. N., Capps, N. E., McDowell, I. F. W., Humphries, S. E., & Neil, A. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000692 · Cited by 5
Cost-effectiveness evaluation of the use of PCSK9 inhibitors
Civeira, F., & Pedro‐Botet, J. (2021) · Endocrinología Diabetes y Nutrición (English ed ) · doi:10.1016/j.endien.2021.05.003 · Cited by 5
Pharmacogenomic approaches to lipid-regulating trials
Bertrand, M.-J., Dubé, M., & Tardif, J. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000351 · Cited by 4
Is it time to reconcile HDL with cardiovascular diseases and beyond? An update on a paradigm shift
Martinez, L. O., Ingueneau, C., & Genoux, A. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000705 · Cited by 4
Biesecker, L. G. (2021) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2021.03.015 · Cited by 4
Evaluación del coste-efectividad de la utilización de los inhibidores de PCSK9
Civeira, F., & Pedro‐Botet, J. (2021) · Endocrinología Diabetes y Nutrición · doi:10.1016/j.endinu.2021.05.001 · Cited by 4
Metabolism of lipoprotein(a): new findings, implications and outstanding issues
Chan, D. C., & Watts, G. F. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000678 · Cited by 3
Editorial comment: hazards of interpreting genetic reports
Lazarte, J., & Hegele, R. A. (2021) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000738 · Cited by 3
Self-citationIschemic Event Reduction and Triglycerides
Dron, J. S., & Hegele, R. A. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.04.071 · Cited by 1
Self-citation
Research works printed but not linked: 9
- Feingold, 2000, Introduction to lipids and lipoproteins
- Voight, 2012, Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study, Lancet., 380, 572, 10.1016/S0140-6736(12)60312-2 · DOI · Paper page
- Berg, 2002, U.S. Preventive Services Task Force: screening for lipid disorders in adults: recommendations and rationale, Am J Nurs., 102, 91
- Tsai, 2005, Falsely low LDL-cholesterol concentrations and artifactual undetectable HDL-cholesterol measured by direct methods in a patient with monoclonal paraprotein, Clin Chim Acta., 358, 192, 10.1016/j.cccn.2005.02.008 · doi:10.1016/j.cccn.2005.02.008
- Koch, 2020, New Sampson low-density lipoprotein equation: better than Friedewald and Martin-Hopkins, Clin Chem., 66, 1120, 10.1093/clinchem/hvaa126 · doi:10.1093/clinchem/hvaa126
- Vinger, 1970, Ocular manifestations of hyperlipoproteinemia, Am J Ophthalmol., 70, 563, 10.1016/0002-9394(70)90890-1 · doi:10.1016/0002-9394(70)90890-1
- Hall, 2012, The best diagnosis is: eruptive xanthoma, Cutis., 90, 12
- US Food and Drug Administration., 2021, Statins: drug safety communication—FDA requests removal of strongest warning against using cholesterol-lowering statins during pregnancy
- Kuehn, 2021, Evinacumab approval adds a new option for homozygous familial hypercholesterolemia with a hefty price tag, Circulation., 143, 2494, 10.1161/CIRCULATIONAHA.121.055463 · doi:10.1161/circulationaha.121.055463
Cited by
Familial chylomicronemia syndrome: An expert clinical review from the National Lipid Association
Javed, F., Hegele, R. A., Garg, A., Patni, N., Gaudet, D., Williams, L., Khan, M., Li, Q., & Ahmad, Z. (2025) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2025.03.013 · Cited by 60
Self-citationAdvances in treatment of Dyslipidemia
Dybiec, J., Baran, W., Dąbek, B., Fularski, P., Młynarska, E., Radzioch, E., Rysz, J., & Franczyk, B. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713288 · Cited by 55
Kamrul-Hasan, A. B. M., Dutta, D., Nagendra, L., Mondal, S., Bhattacharya, S., & Kalra, S. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.08.013 · Cited by 17
Huang, Y., Wang, Y., Xiao, Z., Yao, S., Tang, Y., Zhou, L., Wang, Q., Xie, Y., Zhang, L., Zhou, Y., et al. (2023) · BMC Cardiovascular Disorders · doi:10.1186/s12872-023-03580-6 · Cited by 16
Sydhom, P., Al-Quraishi, B., Gohar, A., El-Shawaf, M., Shehata, N., Ataya, M., Sydhom, M., Awwad, N., Motawade, H., Naji, N., et al. (2026) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-025-07798-8 · Cited by 5
“In contrast, secondary dyslip-idemias often occur in the context of metabolic syndrome and are commonly associated with obesity, alcohol intake, sedentary lifestyle, and type 2 diabetes [1, 2].”
Metadata
- Authors
- Berberich, A. J., & Hegele, R. A.
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2021-10-22
- Volume
- 43
- Issue
- 4
- Pages
- 611-653
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- OpenAlex
- W3205422331
- Cited by
- 469
- References
- 332
- FWCI
- 53.38
- Type
- journal article
- Language
- en
- Open access
- hybrid
- Funders
- Canadian Institutes of Health Research
- Heart and Stroke Foundation of Ontario (G-21-0031455)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.